Poly Medicure Ltd (POLYMED) Q1 FY27 Earnings Call: EBITDA Margin Beats Guidance at 28%, Reaffirms Rs. 2,300-2,400 Cr Revenue Guidance

Poly Medicure Ltd held its Q1 FY27 earnings call on August 07, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Standalone Revenue of Rs.431 Cr; Margins Above Guidance Range

• Consolidated revenue of Rs.525 Cr in Q1 FY 2026-2027, up 30.3% reported YoY (+12.4% organic), including Rs.72.3 Cr from acquisitions.
• Standalone revenue of Rs.431 Cr in Q1 FY 2026-2027, up 12.6% YoY, with domestic at Rs.146 Cr (+16.2%) and international at Rs.281.8 Cr (+10%).
• Standalone EBITDA margin of 28.0% in Q1 FY 2026-2027, 100 bps above the 25-27% full-year guidance range; management expects full-year margins toward the upper end of the band.
• Consolidated EBITDA margin of 24.1% in Q1 FY 2026-2027, within the 23-25% FY 2026-2027 guidance band.
• Consolidated gross margin improved to 73.4% in Q1 FY 2026-2027, up 495 bps YoY, benefiting from higher-margin acquired businesses.
• Cash balance of Rs.855 Cr as of Q1 FY 2026-2027, reserved for strategic organic and inorganic initiatives, per management.

Infusion Therapy Up 11.1%; Europe Rebounds 17.6% Organically

• Infusion therapy segment grew 11.1% in Q1 FY 2026-2027; domestic infusion alone grew 20%+, indicating robust India demand.
• Europe revenue recovered sharply in Q1 FY 2026-2027 — 43.8% reported (+17.6% organic) — driven by demand rebound and new customer acquisitions after a weak prior-year base.
• Cardiology segment reached Rs.28.6 Cr in Q1 FY 2026-2027 (including Pendragon), supported by a Rs.3.3 Cr Government of India grant for clinical studies on import-substitution devices.
• Orthopedics contributed Rs.49.2 Cr in Q1 FY 2026-2027; Renal declined 3.8% to Rs.43.2 Cr due to pricing pressure from Chinese imports via the ASEAN FTA.
• Middle East & Rest of World organic growth slowed to 4.0% in Q1 FY 2026-2027, with the Middle East declining 32% from the West Asia crisis; management noted demand is intact but logistics bottlenecks persist.
• Vascular segment dependence reduced to 50% of total portfolio as of Q1 FY 2026-2027, reflecting diversification into high-technology, platform-based businesses (dialysis, IV therapy).

Gross Margin Overshoots Guidance; Employee Costs Climb 29% YoY

• Standalone gross margin of 71.5% in Q1 FY 2026-2027 exceeded the guided 68-69% range, driven by favourable product mix, price hikes, and inventory gains; management expects some correction in Q2.
• Employee costs rose 29% YoY in Q1 FY 2026-2027, reflecting a 35% minimum wage increase in Haryana and new headcount additions.
• Cash conversion cycle held at ~140 days as of Q1 FY 2026-2027, unchanged from March FY 2025-2026; management cited geopolitical tensions, war, and high oil prices as headwinds to working capital recovery, with no near-term improvement guided.
• Logistics costs increased ~2-3x in the six months prior to Q1 FY 2026-2027, threatening export competitiveness unless they decline, per management.
• Standalone gross margin for full FY 2026-2027 is expected to normalize to 67-69%; consolidated gross margin guided at 71-72%, reflecting 200-300 bps improvement from acquired entities' higher margins.
• Raw material costs are not expected to see major impact in Q2 FY 2026-2027, as crude appears to have peaked, per management.

Target to Double Revenue by FY30; New Facilities from Q4 FY27

• Management targets doubling turnover by FY 2029-2030 under the "Polymed 3.0" strategy (verbatim: "double revenue by FY30"), implying an ~18% CAGR — ~14-15% organic and ~3-4% inorganic, maintaining the ~80/20 split.
• New Faridabad/Palwal facility expected to come online by Q4 FY 2026-2027 (March 2027), focused on orthopedics, transfusion, and infusion capacity expansion.
• New Noida facility for cardiology expansion expected to become commercially operational in Q1 FY 2027-2028.
• CAPEX guidance of Rs.200-225 Cr for FY 2026-2027; management expects asset turnover of 1.2x-1.4x for the new capacity.
• Company holds 399 global patents and distributes to 125 countries, which management cites as evidence of breakthrough technology and market leadership, particularly in infusion therapy.
• 25-30 new products per year continue, with cardiology launches expected over FY 2027-2029; a pipeline of 25 new CE-marked products is expected over the next 3-4 months.

Middle East Logistics Disruptions; Anti-Dumping Probe on Dialyzer Imports

• Middle East orders remain stalled due to shipping container shortages; management expects >20-25% growth once geopolitical conditions improve, but flagged no near-term resolution.
• US tariff exposure is minimal — current duty at 10%, with US exports estimated at $3.5-4 million for FY 2026-2027; management sees no material impact from tariff changes.
• Organic export growth was ~10-11% in Q1 FY 2026-2027; the remaining nine months must achieve >15% to meet the full-year target, with Europe and Southeast Asia as key drivers.
• Government initiated an anti-dumping investigation on dialyzer imports from China and Malaysia (verbatim: "Government initiated an anti-dumping investigation on dialyzer imports from China and Malaysia"); the company claimed an injury margin of 20%, with resolution expected by end of FY 2026-2027.
• Renal segment degrew ~3% in Q1 FY 2026-2027 due to Chinese dumping via the ASEAN FTA (zero import duty); management targets a recovery to 15-18% (close to 20%) growth by end of FY 2026-2027.
• Cross-sell synergies from Pendra Care and CTF acquisitions expected to become visible from FY 2027-2028, pending regulatory approvals for product registration.

FY27 Revenue Guidance Reaffirmed at Rs.2,300-2,400 Cr Consolidated

• FY 2026-2027 consolidated revenue guidance maintained at Rs.2,300-2,400 Cr, including Pendragon and CTFE full-year consolidation.
• FY 2026-2027 standalone revenue guidance maintained at Rs.1,900-2,000 Cr, with domestic growth >20% and international growth >15%.
• FY 2026-2027 standalone EBITDA margin guided at 25-27%; consolidated EBITDA margin guided at 23-25%; management expects standalone margins toward the upper end.
• Inorganic sales contributed ~Rs.73 Cr to export revenues in Q1 FY 2026-2027; Penpol Care faced degrowth due to ~20% Middle East exposure, while CTS grew mid-to-high single digits.
• Board allocated funds for a direct sales expansion in Brazil following a small acquisition, and for technology acquisitions in cardiology, oncology, and orthopedics.
• Key leadership appointments: Indranil Mukherjee as CEO India & APAC (joined 1 June 2026), Renato Rocca as CEO Brazil (joined 1 August 2026), and Abhimanyu Huda as Head of Renal Business in India.